Cagrilintide for Weight Loss
Research, mechanism, dosing, and effectiveness of Cagrilintide for weight loss.
Quick Answer
Cagrilintide is a long-acting amylin analog being studied for obesity.
Evidence Level
Human Trials
Typical Dose
Clinical trial doses up to 4.5 mg weekly
Results Timeline
Weight loss over months in trials
FDA Status
Research Only
How Cagrilintide Works for Weight Loss
Mimics amylin to reduce appetite and slow gastric emptying.
About Weight Loss
Reduction of body fat and overall body weight through appetite control and metabolic enhancement.
Research Evidence
REDEFINE 1 Phase 3 trial showed 11.8% weight loss with cagrilintide monotherapy vs 2.3% placebo over 68 weeks. Combined with semaglutide (CagriSema), average weight loss reached 20.4% vs 3.0% placebo. 60% of CagriSema participants achieved ≥20% weight loss, and 23% lost ≥30%. This represents some of the most significant weight loss results seen with any anti-obesity medication.
Dosing for Weight Loss
Recommended Dose
Clinical trial doses up to 4.5 mg weekly
Frequency
Once weekly
Administration
Subcutaneous injection once weekly
Duration
Long-term / chronic use expected
Note: Most effective when combined with semaglutide (CagriSema). Works through amylin pathway which is complementary to GLP-1 mechanism. Dose escalation typically used to minimize GI side effects. Not yet commercially available - still in clinical trials.
What to Expect
Initial adjustment period. Some users may notice subtle changes.
Early benefits often become noticeable. Continue consistent use.
Most users report meaningful improvements by this point.
Full effects typically realized. Reassess and adjust as needed.
Possible Side Effects
Not everyone experiences these. Individual responses vary.
- •Nausea (common, usually transient)
- •Vomiting
- •Diarrhea
- •Constipation
- •Abdominal pain
- •Injection site reactions
Frequently Asked Questions
Does Cagrilintide help with weight loss?
Cagrilintide is a long-acting amylin analog being studied for obesity.
How does Cagrilintide work for weight loss?
Mimics amylin to reduce appetite and slow gastric emptying....
What dose of Cagrilintide should I use for weight loss?
Clinical trial doses up to 4.5 mg weekly
How long until I see results?
Weight loss over months in trials
Other Peptides for Weight Loss
These peptides are also researched for weight loss.
Semaglutide
FDAA GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.
Liraglutide
FDAAn FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management. The predecessor to semaglutide with daily dosing.
Retatrutide
Clinical TrialsA triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 trials show up to 28.7% weight loss (71 lbs average), the highest of any obesity drug. Expected FDA approval late 2026 to early 2027.
Survodutide
Clinical TrialsA dual GLP-1/glucagon receptor agonist in development for obesity and MASH. Has FDA Breakthrough Therapy Designation for MASH with fibrosis.
Educational Information Only
This information about Cagrilintide for weight loss is for educational purposes only. Always consult with qualified healthcare providers before using any peptide. Individual results may vary.